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Therapeutic benefit of spironolactone in experimental chronic is characterized by derangement of renal function and
cyclosporine A nephrotoxicity. architecture. Renal dysfunction seems to be the result
Background. Cyclosporine A (CsA) is an immunosuppres- of enhanced vasoconstrictor factors release, particularlysive drug used to prevent tissue allograft rejection. However,
due to increased endothelin production and to the activa-its long-term utilization is limited due to chronic nephrotoxicity
tion of the renin-angiotensin-aldosterone system (RAAS)for which no prevention is available. This study evaluated the
effect of spironolactone on renal functional and structural alter- [2–5], while the structural damage, such as arteriolopathy
ations induced by CsA, and assessed whether the protective and tubulointerstitial fibrosis, appears to be the conse-
effect was associated with a reduction of transforming growth quence of several mechanisms including hypoxia, freefactor- (TGF-) and the change of extracellular matrix pro-
radical production and up-regulation of transformingtein mRNA level.
growth factor-1 (TGF 1) synthesis [6–11]. The increaseMethods. Male Wistar rats fed with low sodium diet were
divided in four treatment groups: vehicle, CsA (30 mg/kg), spiro- in this profibrotic cytokine, TGF-1, results in the activa-
nolactone (20 mg/kg), or CsAspironolactone. After 21 days, tion of extracellular matrix protein synthesis, such as
creatinine clearance (CCr), blood CsA, arteriolopathy in renal collagen I and fibronectin [10, 12] as well as an increasetissue, and TGF-, collagen I, collagen IV, fibronectin, and epi-
in the renal apoptosis index [7, 13, 14], which are knowndermal growth factor (EGF) mRNA levels in renal cortex were
determined. to be associated with the development of kidney injury.
Results. CsA reduced the CCr and up-regulated TGF-, colla- In addition, it has been shown recently that epidermal
gen I and fibronectin mRNA expression with a significant devel- growth factor (EGF), which mediates regeneration in
opment of arteriolopathy, and reduced EGF mRNA levels. In
tubular cells after renal damage, is significantly reducedcontrast, spironolactone administration prevented the fall in re-
during chronic CsA nephrotoxicity [14]. Thus, the reduc-nal function and TGF-, collagen I, and fibronectin up-regula-
tion, together with a reduction of arteriolopathy and tubulo- tion in EGF might contribute to enhance the structural
interstitial fibrosis. changes observed in this condition.
Conclusion. Our data show that aldosterone plays an impor- Considerable attention has been directed to angioten-tant role as a mediator of renal injury induced by CsA. Thus,
sin II (Ang II) as a mediator of renal damage progressionmineralocorticoid receptor blockade may be a potential strat-
observed in several nephropathies, including chronicegy to prevent CsA nephrotoxicity.
CsA toxicity. As a consequence, a therapeutic advantage
has been observed with the use of angiotensin-enzyme-
converting (ACE) inhibitors or Ang II receptor antago-Long-term cyclosporine (CsA) immunosuppressive
therapy in allograft recipients and in patients with auto- nists to retard the progression rate of renal failure in
immune diseases has been limited due to the concomi- the clinical setting, including the chronic nephropathy
tant development of chronic nephrotoxicity [1], which associated with diabetes mellitus [15–17]. Although aldo-
sterone is part of the renin-angiotensin-aldosterone axis,
little attention has been addressed to this mineralocorti-Key words: aldosterone, arteriolopathy, interstitial fibrosis, TGF-,
renal function, low sodium diet, mineralocorticoid therapy. coid as a potential key molecule mediating renal damage.
Recent studies suggest that aldosterone could play anReceived for publication January 22, 2002
important role in the progression of renal disease. Con-and in revised form July 17, 2002
Accepted for publication August 12, 2002 tinuous infusion of aldosterone in normal rats induced
up-regulation of TGF- mRNA in the kidney (abstract; 2003 by the International Society of Nephrology
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Juknevicius et al, J Am Soc Nephrol 11:622A, 2000) and urine, V is the urine flow rate and P is plasma concentra-
tion. In all studied groups urinary protein excretion wasthe inhibition of aldosterone actions with the aldosterone
receptor blocker, spironolactone, reduced renal damage determined using the trichloroacetic acid (TCA) turbidi-
metric method [22], and serum aldosterone and potas-without lowering blood pressure in both the renal ablation
model and the stroke-prone spontaneously hypertensive sium levels were determined by radioimmunoassay (RIA)
and with a NOVA4 electrolyte analyzer (NOVA Bio-rat [18–20]. Hostetter et al speculated that the mecha-
nism by which mineralocorticoids promote renal injury medical, Waltham, MA, USA), respectively. Blood CsA
concentration also was determined by monoclonal radio-in these models could be explained by the up-regulation
of TGF-1 induced by aldosterone [21]. In this regard, immunoassay kit (TDx/TDxFLx; Abbott Laboratories,
Abbot Park, IL, USA) in groups receiving CsA.the structural injury that is observed in the chronic CsA
nephropathy model in the rat (induced by administration Kidneys were obtained from six rats of each group for
histological study. Rats were anesthetized by intraperito-of CsA in animals fed a low salt diet) has been associated
with an increase in TGF-1 expression [9, 10], which can neal injection of sodium pentobarbital and their kidneys
were excised, macroscopically divided into renal cortexbe partially abrogated by the concomitant administration
of the Ang II receptor antagonist losartan [9]. However, and medulla, frozen in liquid nitrogen, and kept at80C
until used.because losartan administration also will result in a re-
duction of aldosterone release, it is unknown if the pro-
Histological studiestective effect of losartan is due to blockade of the Ang II
receptors in the kidney, by the reduction of aldosterone Before renal cortex separation, one half of the left
kidney was taken and fixed in alcoholic Bouin’s solutionsecretion, or by a combination of both mechanisms.
Our present study used a model of chronic CsA nephro- for light microcopy studies. After an appropriate dehy-
dration, kidney slices were embedded in paraffin, sec-toxicity and showed that spironolactone administration
tioned at 3 , and periodic acid-Schiff (PAS), Van Giesoneffectively prevented renal dysfunction and up-regulation
and trichromic stains were performed. Arteriolopathyof TGF-1 and extracellular matrix proteins mRNA, and
percentage was determined by counting at least 100 af-reduced the structural damage induced by CsA. These
ferent arterioles showing the characteristic lesion of thisdata suggest that aldosterone is a key molecule in the
model. Arteriolopathy was counted as present or non-pathogenesis of chronic CsA nephropathy.
present (dichotomic variable). Thus, the results are ex-
pressed as the percentage of affected arterioles over total
METHODS number of arterioles. The degree of tubulointerstitial fi-
The present study utilized the chronic CsA nephrotox- brosis was evaluated by morphometry. For this purpose,
icity model in the rat that is produced by the administra- ten subcortical periglomerular fields per Van Gieson
tion of CsA and a low sodium diet. Four groups of twelve stained section (magnification,200) were randomly se-
male Wistar rats, weighing 350 g and fed with low salt diet lected in kidneys from the different groups. The images
(0.02%), were included in the study. Group I (V) animals were recorded and the affected areas were delimited and
received 0.1 mL SC of olive oil as the vehicle every 24 semiquantified using the Leica processing and analysis
hours. Group II (CsA) rats were treated with a daily dose system Ltd., (Leica Imaging System Ltd., Cambridge,
of CsA 30 mg/kg SC. Group III (SPIRO) received 20 mg/ UK). Finally, the proportion of fibrosis was calculated
kg/day of spironolactone by gastric gavage, and group dividing the interstitial fibrosis by total area. The histo-
IV comprised rats treated with CsASPIRO. All animals logical analysis was performed without knowing the
were treated during 21 days. The V and SPIRO groups group at which each kidney belonged.
were pair-fed with the CsA and CsASPIRO groups,
Molecular studiesrespectively.
RNA isolation. Total RNA was isolated from each re-
Functional studies nal cortex or medulla following the guanidine isothyocia-
Systolic blood pressure was measured by a non-inva- nate-cesium chloride method [23]. Integrity of isolated
sive tail cuff method at the end of the experimental total RNA was examined by 1% agarose gel electrophore-
protocol (Model 179, IITC Life Science, Woodland Hills, sis and RNA concentration was determined by UV-light
CA, USA). All animals were placed in metabolic cages absorbance at 260 nm (Beckman DU640, Brea, CA, USA).
and urine that was spontaneously voided during every Northern blot analysis. Aliquots of 20g of total RNA
24 hours was collected. Serum and urine creatinine con- from each renal cortex sample were separated by 0.9%
centration were measured with an autoanalyzer (Tech- agarose/formaldehyde gel electrophoresis and transferred
nicon RA-1000; Bayer Co. Tarrytown, NY, USA). Renal to a nylon membrane (Biotrans; ICN, East Hills, NY,
creatinine clearances were calculated by the standard USA), and fixed by UV cross linking (Stratalinker; Strata-
gene, La Jolla, CA, USA). The probes used were TGF-1,formula CCr  U · V/P, where U is the concentration in
Feria et al: Spironolactate in cyclosporine A nephrotoxicity 45
collagen alpha I chain and collagen alpha IV chain ob- Statistical analysis
tained from mouse, as well as fibronectin and glyceralde- The results are presented as mean  SEM. The sig-
hyde-3-phosphate dehydrogenase (GADPH) from rat. nificance of the differences between groups was tested
Labeling of cDNA probes was done using the Random by analysis of variance (ANOVA) comparison using
Primer Labeling Kit (Boehringer, Mannheim, Germany) Bonferroni’s correction for multiple comparisons. Statis-
and [	32P]-dCTP (Amersham, Little Chalfont, Bucking- tical significance was defined as two-tailed P 
 0.05.
hamshire, UK) accordingly to the manufacturer’s instruc-
tions. Hybridization was performed overnight at 42C in
RESULTS5  standard sodium citrate (SSC), 50 mmol/L sodium
Physiological and functional studiesphosphate (pH 6.8), 50% formamide, 5 Denharts solu-
tion, 0.1% sodium dodecyl sulfate (SDS), and 250 g/mL All treatments were well tolerated by all rats along
of Torula yeast total RNA. Membranes were washed the study. The CsA and CsASPIRO groups lost body
three times for 10 minutes at room temperature in 2  weight gradually over 21 days of treatment. Mean body
weights for these groups were 355.4  6.2 and 353.6 SSC, 0.1% SDS, and twice for 45 minutes at 68C in
1.68 g, respectively, at the beginning of the experiment0.1  SSC, 0.1% SDS. Autoradiographs were scanned
and 276.2  4.1 and 294.0  7.4 g, respectively, at theand the hybridization bands were measured by densito-
end. In contrast, the V and VSPIRO groups that weremetric analysis.
pair-fed showed a slight gain in body weight during theSemiquantitative RT-PCR. The relative level of EGF
study. The initial body weights were 358.5  4.2 andand GAPDH mRNA expression was assessed in the renal
356.3  6.0 g, respectively, and final body weights werecortex by semiquantitative reverse transcription-poly-
384.75  5.8 and 369.1  7.1 g, respectively.merase chain reaction (RT-PCR), as previously described
Figure 1 depicts the most important physiological pa-[24, 25]. Briefly, primer sequences [26, 27] were custom
rameters that were evaluated in control and experimen-obtained from Invitrogen (Gaithersburg, MD, USA).
tal groups. After 21 days, systolic blood pressure (SBP)Reverse transcription (RT) was carried out using 10g
was measured. As has been previously reported by sev-of total RNA from the renal cortex of each rat. RT was
eral authors [7, 12, 14, 28], CsA administration in thisperformed at 37C for 60 minutes in a total volume of
experimental model is not associated with hypertension.20L using 200 U of the Moloney murine leukemia virus
SBP in the control group was 125.5  3.4 whereas itreverse transcriptase (Invitrogen), 100 pmol of random
was 132.6  8.6 mm Hg in CsA treated rats (P  NS).hexamers (Invitrogen), 0.5 mmol/L of each dNTP (Sigma
Spironolactone also had no effect in SBP (123.5 Chemical Co., St. Louis MO, USA), and 1 RT buffer
3.1 mm Hg). Thus, all of the rats studied were normoten-[75 mmol/L KCl; 50 mmol/L Tris-HCl; 3 mmol/L MgCl2; sive. As shown in Figure 1B, the amount of proteins in
10 mmol/L dithiothreitol (DTT), pH 8.3]. One tenth of
urine was not different among the groups, and although
the RT from each individual sample was used for EGF,
the proteinuria levels were less in CsA treated rats, as
and GAPDH amplification in 20 L final volume reac- reported previously [12], this difference was not statisti-
tions containing 0.2Ci of [	32P]-dCTP (3000 Ci/mmol, cally different. In order to evaluate the effect of cyclospo-
9.25 MBq, 250 Ci). PCR cycles were performed in a rine and spironolactone on the well known increase in
DNA thermal cycler (M.J. Research, Watertown, MA, serum potassium levels produced by these compounds,
USA). The control gene was amplified simultaneously serum potassium was determined in all four groups. As
in each reaction. Amplification kinetics for EGF and the Figure 1C shows, CsA administration resulted in hyper-
housekeeping gene GAPDH in renal cortex total RNA, kalemia since the serum potassium in this group was
and the optimal number of cycles for each primer pair 4.3  0.3 mEq/L, which is significantly different to the
were assessed as we previously reported [24, 25]. To control group (3.4 0.2 mEq/L, P
 0.05). Serum potas-
analyze the PCR products, one-half of each reaction was sium in the CsASPIRO group was 4.4  0.2 mEq/L.
electrophoresed in a 5% acrylamide gel. Bands were Thus, spironolactone administration had no further ef-
ethidium bromide stained and visualized under UV light, fect on serum potassium levels. Finally, it is well known
cut out, suspended in 1 mL of scintillation cocktail (Eco- that a low sodium diet activates aldosterone production.
lume; ICN, Aurora, OH, USA), and counted by liquid Figure 1D shows a significant increase in aldosterone
scintillation (Beckman LS6500). All reactions were per- levels in all of the groups studied. Although values were
formed individually from each cortex total RNA in dupli- slightly higher in rats receiving spironolactone, the differ-
cate. Genomic DNA contamination was checked by ences were not significant.
treating all RNA samples with RNAse-free DNAase I To evaluate the effect of aldosterone inhibition with
and by carrying samples through PCR procedure without spironolactone on renal function, creatinine clearance
(CCr), as an index of glomerular filtration rate, was mea-adding reverse transcriptase.
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Fig. 1. (A) Systolic blood pressure, (B ) uri-
nary protein excretion, (C ) serum potassium,
and (D) serum aldosterone levels in the vehicle
group (), CsA treated animals ( ), SPIRO
group ( ) and CsASPIRO treated rats ().
*P
 0.05 vs. V, SPIRO. Although not shown,
serum aldosterone levels in rat fed with nor-
mal salt diet are around 100 pg/mL.
CsASPIRO rats of 3594  133 ng/mL was 14% lower
than the value of 4199 99 ng/mL obtained in rats treated
with CsA alone. Although the reduction was statistically
significant (P 
 0.05), it does not explain the protection
conferred by spironolactone in CsA-treated animals, since
the blood CsA concentration was still within the toxic
range reported by other investigators [10, 11, 14]. In ad-
dition, it is known that one tenth of CsA is metabolized
in the kidney. Accordingly, it is feasible that the small
reduction in CsA blood levels observed in CsASPIRO
group could be secondary to the restoration of renal
function.
Fig. 2. Glomerular filtration rate estimated by creatinine clearance in
vehicle group (), animals treated with CsA during 21 days with 30 Histological studiesmg/kg ( ), SPIRO group ( ) and CsASPIRO treated rats () main-
taining on low sodium diet, *P
 0.05 vs. V, SPIRO, and CsASPIRO To establish if aldosterone receptor blockade with
groups. spironolactone also reduces or prevents the structural
damage induced by CsA administration, the degree of
afferent arteriolopathy and tubulointerstitial fibrosis was
sured at the end of the 21 days of treatment in the four quantified. The percentage of arteriolopathy was ob-
groups of rats. As shown in Figure 2, the administration tained by counting at least 100 preglomerular afferent
of CsA resulted in a significant reduction in the glomeru- arterioles in each rat. A representative light microscopy
lar filtration rate, from 1.49 0.1 mL/min in the V group image of the characteristic arteriolar lesion of CsA ne-
to 0.72  0.1 mL/min in CsA group, whereas inhibition phropathy is shown in Figure 3A. This alteration was
of aldosterone with spironolactone in the VSPIRO mainly located in the preglomerular afferent arteriole
group had no effect on this parameter (1.58  0.2 mL/ and extended several microns upstream, consisting of an
min). Interestingly, spironolactone administration pre- enlargement of the smooth muscle cells and resulting in
vented the fall in renal function induced by CsA treat- a partial or total narrowing of the arteriolar lumen. The
ment, since the CCr in the CsASPIRO treated rats was affected cell cytoplasm showed eosinophylic, PAS posi-
1.34  03 mL/min. This CCr value was not statistically tive, homogeneous or granular degeneration. Endothe-
different from values observed in V and VSPIRO con- lial cells looked prominent and perivascular cells seemed
trol groups. To differentiate if the protective effect of proliferated. The percentage of afferent arterioles show-
spironolactone was related to a decrease in CsA blood ing this kind of lesion is shown in Figure 3B. As we
levels, we assessed the CsA concentration in blood from previously reported [29], in the control group treated
with vehicle alone, a few afferent arterioles were shownCsA and CsASPIRO groups. The value observed in
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Fig. 3. (A) Afferent arteriolopathy in CsA
treated rat during 21 days (PAS stain 350).
(B) Percentage of afferent arterioles injured,
which was estimated in at least 100 preglomer-
ular afferent arterioles from vehicle group
(), CsA treated animals ( ), SPIRO group
( ) and CsASPIRO treated rats (). *P 

0.05 vs. V, SPIRO and CsASPIRO groups,
and †P 
 0.05 vs. V, SPIRO and CsA groups.
Fig. 4. (A) Tubulointerstitial fibrosis observed
in a salt depleted rat treated with CsA (Van
Gieson stain 200). (B) Mean percentage of
injured area obtained in at least ten fields.
*P 
 0.05 vs. V, SPIRO and CsASPIRO
groups and †P 
 0.05 vs. V, SPIRO and CsA
groups.
to have arteriolopathy (2.6%), possibly as a result of the Northern blot analysis of total RNA from renal cor-
tex using specific probes for TGF-, collagen I, collagenactivation of the RAAS system induced by a low sodium
diet. This low frequency of arteriolopathy was similar in IV, and fibronectin are shown in Figure 5, together with
the Northern blot analysis of the housekeeping genethe SPIRO group. In contrast, as expected, in the chronic
CsA group, arteriolar lesion was present in as much as GAPDH that was used to control each experiment. The
densitometric analysis of TGF-1 is shown in Figure 6.28% of glomeruli, whereas this percentage of arteriolo-
pathy was reduced to 14% in the CsASPIRO group. In contrast to vehicle-treated animals, CsA administra-
tion in sodium-depleted rats produced a marked increaseThe photomicrograph presented in Figure 4A is a
representative example of the tubulointerstitial fibrosis in TGF-1 mRNA levels. The TGF-/GAPDH ratio was
1.1  0.1 in the vehicle group and 4.5  0.5 in the CsAobserved in CsA sodium-depleted animals. The morpho-
metric analysis is shown in Figure 4B. As expected, signif- group (P 
 0.01). The administration of aldosterone an-
tagonist spironolactone had no effect on TGF-1 mRNAicant tubulointerstitial fibrosis was observed in the group
receiving CsA. In contrast, spironolactone was able to expression, since the TGF-/GAPDH ratio in the SPIRO
group was 1.6  0.1. In contrast, in CsASPIRO groupreduce this alteration. These observations suggest that
at least part of the CsA-induced arteriolar and tubulo- the TGF-/GAPDH ratio was 2.0  0.4. This value was
significantly lower than the expression observed in theinterstitial lesions are mediated by aldosterone, and dem-
onstrates that spironolactone not only prevents the nega- CsA group (2.0  0.4 vs. 4.5  0.5, P 
 0.05), but not
different to the value observed in the SPIRO grouptive effects of CsA at the functional, but also at the
structural level. (2.0 0.4 vs. 1.6 0.1, PNS). Accordingly, spironolac-
tone administration prevented the TGF-1 up-regula-
Molecular studies tion induced by CsA.
The effects of CsA and spironolactone on the expres-To begin to understand the mechanisms by which spi-
sion of extracellular matrix proteins such as collagen I,ronolactone protects the kidney from CsA toxicity, we
collagen IV, and fibronectin mRNAs in renal cortex areevaluated the gene expression level of extracellular ma-
trix proteins that are known to be involved in the patho- shown in Figure 7. Chronic CsA nephrotoxity was associ-
ated with a fivefold up-regulation of collagen I. The ratiogenesis of chronic renal injury. The autoradiographs of
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Fig. 5. Northern blot analysis of mRNA from
renal cortex of the four study groups using
specific probes for TGF-1, collagen I, colla-
gen IV, fibronectin and GAPDH. Each lane
was loaded with 20 g of total RNA from a
different rat, corresponding to each group as
stated.
significance with ANOVA for multiple comparisons (V
group 0.36  0.01 vs. CsA group 0.51  0.07, t  2.77,
P  0.05). However, the ratio of collagen IV/GAPDH
observed in the CsASPIRO group (0.18  0.03) was
significantly lower than the ratio in the CsA treated
group (0.51 0.07, t 6.1, P
 0.01). Thus, CsA induced
up-regulation of extracellular matrix proteins mRNA in
renal cortex, and this effect of CsA was prevented when
spironolactone was simultaneously administered.
It has been suggested previously that down-regulation
of the EGF contributes to the structural damage induced
by toxic agents, including CsA [14, 30], since EGF is a
Fig. 6. TGF-1 mRNA levels in renal cortex are represented as the potent mitogenic agent and its expression has been asso-ratio between TGF-1 and GAPDH bands densitometry in vehicle group
ciated with renal repair following ischemic injury. Thus,(), CsA-treated animals ( ), SPIRO group ( ) and CsASPIRO
treated rats (). *P
 0.05 vs. V, SPIRO and CsASPIRO groups and we analyzed the effect of CsA and spironolactone on the
†P 
 0.05 vs. CsA group. EGF mRNA levels in renal cortex following a semi-
quantitative RT-PCR strategy. The upper panel of Fig-
ure 8 shows the PCR products obtained for each rat and
the lower panel shows the mean ratio between EGFof collagen I/GAPDH in the CsA group was 3.8  0.9,
and GAPDH of each group. CsA treatment induced awhereas in the V group it was 0.6  0.05, P 
 0.01. This
significant reduction in the expression of EGF as com-up-regulation of collagen I induced by CsA was abro-
pared to the V group (1.5 0.1 vs. 3.9 0.1, respectively,gated by spironolactone, since the ratio in CsASPIRO
P 
 0.01). Interestingly, spironolactone alone also in-group was 1.6 0.3. A similar observation was obtained
duced a slight decrease in EGF mRNA levels (3.0  0.1in the analysis of fibronectin mRNA expression that is
SPIRO, P 
 0.05 vs. V group). However, when spirono-shown in Figure 7B. The ratio of fibronectin/GAPDH in-
lactone was administered with CsA, the ratio of EGF/creased in CsA treated rats and this up-regulation was
GAPDH was 2.2  0.3. This value was significantlyprevented by spironolactone. The values of the ratio be-
higher than the value observed in the CsA group, sug-tween collagen IV and GAPDH are shown in Figure 7C.
gesting that spironolactone partially reversed the down-The expression of collagen IV in the CsA group was in-
creased, but the difference with the V group did not reach regulation of EGF induced by chronic CsA toxicity.
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Fig. 8. Epidermal growth factor mRNA levels in renal cortex assessed
by RT-PCR. (A) An acrylamide gel showing EGF and GAPDH ampli-
fication bands for all of the study groups. Each lane was loaded with
10 L of the RT-PCR reaction from different animals. (B ) Graphic
representation of the mean ratio between EGF and GAPDH for the
Vehicle group (), CsA-treated animals ( ), SPIRO group ( ) and
CsASPIRO treated rats (). *P 
 0.05 vs. V and †P 
 0.05 vs. CsA
group.
constriction, which is due at least in part to activation
of the renin-angiotensin-aldosterone system (RAAS).
Our data show that CCr of the rats treated with spirono-
lactone and CsA was similar to the vehicle-treated ani-
mals and significantly higher than the CCr observed in
the CsA group (Fig. 2). Therefore, aldosterone receptor
blockade completely prevented the decrease in glomeru-
lar filtration rate induced by CsA. It is unlikely that
this spironolactone-conferred protection was due to the
effect of this diuretic agent on the blood pressure levels,
since this model is not associated with the development
Fig. 7. Effects of CsA and SPIRO on the expression of extracellular of hypertension. SBP was similar among all of the study
matrix proteins. (A) Collagen I, (B) fibronectin and (C ) collagen IV groups. It is also unlikely that protection conferred byin vehicle group (), CsA-treated animals ( ), SPIRO group ( ) and
spironolactone was secondary to the small reduction onCsASPIRO treated rats (). *P 
 0.05 vs. V, SPIRO and
CsASPIRO groups and †P 
 0.05 vs. CsA-treated rats. CsA blood levels observed in the CsASPIRO group.
It has been shown that CsA levels above 1000 pg/mL
are enough to produce renal damage [10, 11, 14]. In
DISCUSSION addition, because it is known that one tenth of CsA is
Using a model of chronic CsA nephrotoxicity in the metabolized in the kidney, the small reduction in CsA
rat, our present study shows that aldosterone receptor blood levels observed in CsASPIRO group was proba-
blockade with spironolactone effectively prevents the bly secondary to the restoration of renal function.
fall in renal function, as well as reduces the arteriolopa- This beneficial effect of spironolactone was associated
thy and tubulointerstitial fibrosis induced by CsA. The with a significant reduction of arteriolopathy and tubulo-
protective effect of spironolactone was associated with interstitial fibrosis, which is the structural hallmark of
prevention of the CsA-induced up-regulation of TGF-, CsA injury in the kidney. Several therapeutic agents such
collagen I, collagen IV, and fibronectin, and partial resto- as endothelin [31] and angiotensin inhibitors [9, 14, 31],
ration of CsA-inducing down-regulation of EGF mRNA vascular endothelial growth factor (VEGF) [28], polysul-
levels in renal cortex. phate pentosan [29] and l-arginine [32, 33] have been
A chronic CsA nephrotoxicity model induced by CsA investigated as possible tools to reduce chronic CsA
nephrotoxicity. However, most of these treatments haveadministration in rats fed with a low salt diet is character-
ized by renal failure accompanied by severe renal vaso- not effectively reduced both functional and structural
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changes induced by CsA in the kidney. Although admin- Increased attention has arisen on aldosterone as a
potentially important mediator of chronic heart failureistration of losartan [9, 14], VEGF [28], and polysulfate
pentosan [29] partially prevented the structural damage and renal disease. The use of spironolactone improves the
survival rate in patients with chronic heart disease [38].induced by CsA, these agents did not improve the renal
dysfunction during chronic CsA nephrotoxicity. Moreover, studies in two different experimental models
of renal disease, one due to hypertension and the otherThe mechanism for arteriolopathy and chronic renal
damage to the kidney induced by CsA is unknown and, due to renal ablation, has shown that aldosterone infu-
sion abrogates the renal protection conferred by Ang IIthus, the mechanism of protection by spironolactone is
not clear. Acute experimental CsA nephrotoxicity is di- inhibition either with ACE inhibitors, or Ang II recep-
tor antagonists. In the model of severe hypertension inrectly related to renal vasoconstriction and this form
of nephrotoxicity can be completely prevented by co- stroke-prone spontaneously hypertensive rats that were
fed with high salt diet, Rocha et al observed that glomer-administration of dexamethasone [34], arginine [35, 36],
or glycine [6] as well as enalapril and spironolactone [4]. ular and vascular lesions were prevented with spironolac-
tone or captopril, and the effect of captopril was reversedThomson et al [4] and Iacona et al [37] observed that
spironolactone improved renal function during acute when rats were treated with aldosterone [19, 20]. In the
renal ablation model, Greene, Kren and Hostetter pro-CsA nephrotoxicity in the rat. In contrast, chronic CsA
toxicity not only involves renal injury due to hypoxia, but vided evidence that aldosterone contributes to the devel-
opment of hypertension and renal injury [18]. In thesealso is due to up-regulation of TGF- and extracellular
matrix proteins [9, 10] as well as an increase in apoptosis rats with 5/6 nephrectomy, losartan and enalapril reduces
proteinuria and nephrosclerosis, but the protection con-[7]. Interestingly, Viera et al have shown up-regulation
of TGF- expression within the afferent arterioles, sug- ferred by these agents was completely avoided when
aldosterone was re-infused to maintain levels compara-gesting that this cytokine not only mediates interstitial
lesions, but also might be a mediator of hypertrophy ble to untreated rats with reduced renal mass. In addi-
tion, selective blockade of aldosterone with epleroneobserved in juxtaglomerular arterioles [11]. Shihab et al
showed that chronic CsA toxicity in the rat is associated reduced proteinuria and glomerulosclerosis in L-NAME
hypertensive rats [39]. Thus, aldosterone seems to playwith up-regulation of TGF- expression, and that this
effect could be prevented by Ang II blockade, either an important role in the progression of renal diseases.
In this regard, recently it has been suggested that patientswith the enzyme converting inhibitor enalapril or the
angiotensin II receptor antagonist losartan [9]. The use with diabetic nephropathy and already treated with ena-
lapril may obtain further benefit by adding spironolac-of these compounds, however, did not prevent renal dys-
function, suggesting that up-regulation of TGF- during tone to their daily treatment [40].
The exact mechanisms by which spironolactone pro-CsA toxicity is independent of renal hemodynamics, and
is mediated, at least in part, directly by Ang II. With our tects the kidney from CsA toxicity are not clear from
our current data and further studies will be necessary tocurrent data, however, we propose that CsA-induced
overexpression of TGF- is not mediated by Ang II. clarify this issue. However, our observation that renal
function was completely restored by spironolactone ad-Instead, it is mediated by aldosterone, since it can be
completely prevented by spironolactone (Fig. 6). In this ministration in CsA-treated rats suggests that, in addition
to its effect on TGF- expression, aldosterone blockaderegard, preliminary evidence shows that aldosterone in-
fusion in normal rats increased TGF- mRNA levels in counterbalances the renal vasoconstriction induced by
CsA. Although the mechanisms for this effect remain tothe kidney (abstract; Juknevicius et al, J Am Soc Nephrol
11:622A, 2000). The chronic model for CsA toxicity is be elucidated, it has been proposed that aldosterone mod-
ulates the vascular tone [41], possibly through increasedproduced in rats that are fed with low salt diet. Hence,
the activity of the renin-angiotensin system is enhanced vasoconstrictive effects of catecholamines [42], impaired
vasodilation in response to acetylcholine [43], up-regula-and this also includes the increased release of aldoste-
rone. Therefore, the beneficial effect of losartan or enala- tion of -adrenergic and Ang II receptors [44–46], and
a direct aldosterone effect, which could be mediated bypril on TGF- expression observed by Shihab et al [9]
is probably the result of decreasing aldosterone release non-genomic mechanisms [41]. The fact that arginine ad-
ministration also prevented renal dysfunction and par-that is expected to occur when angiotensin blockers are
used. In contrast to Shihab et al, we observed that spiro- tially reversed the structural injury during chronic CsA
toxicity [10] suggests that the possible vasodilatory actionnolactone not only prevented the increase in the expres-
sion of TGF- in the renal cortex, but also the functional of spironolactone administration is responsible, at least
in part, for the renal protection observed in our study.and structural damage induced by CsA. Thus, spirono-
lactone appears to be a helpful agent that effectively Epidermal growth factor (EGF) is a 53-amino acid
polypeptide that is known to be important as mediator ofoffers a therapeutic benefit in chronic CsA nephrotoxic-
ity in the rat. renal repair following injury. Recently, Yang et al showed
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11. Vieira JM Jr, Noronha IL, Malheiros DM, Burdmann EA:that chronic CsA nephrotoxicity is associated with a re-
Cyclosporine-induced interstitial fibrosis and arteriolar TGF-betaduction of EGF protein levels in the kidney, which cor- expression with preserved renal blood flow. Transplantation 68:1746–
relates with the degree of fibrosis and apoptosis [14]. 1753, 1999
12. Young BA, Burdmann EA, Johnson RJ, et al: Cellular prolifera-Because these effects were reversed with losartan admin-
tion and macrophage influx precede interstitial fibrosis in cyclospo-istration, the authors proposed that Ang II is the princi-
rine nephrotoxicity. Kidney Int 48:439–448, 1995
pal mediator of tubular injury through its effect on EGF. 13. Ortiz A, Lorz C, Catalan M, et al: Cyclosporine A induces
apoptosis in murine tubular epithelial cells: Role of caspases. Kid-The present study confirms a down-regulation of EGF
ney Int 54(Suppl 68):S25–S29, 1998mRNA levels in the renal cortex of CsA treated rats.
14. Yang CW, Ahn HJ, Kim WY, et al: Influence of the renin-angioten-
We also observed partial restoration of EGF expression sin system on epidermal growth factor expression in normal and
when spironolactone was concomitantly administered cyclosporine-treated rat kidney. Kidney Int 60:847–857, 2001
15. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect ofwith CsA. Thus, our data together with observations by
angiotensin-converting-enzyme inhibition on diabetic nephropa-Yang et al [14] show that blockade of either Ang II or thy. The Collaborative Study Group. N Engl J Med 329:1456–
aldosterone partially abrogates the EGF down-regula- 1462, 1993
16. Lewis EJ, Hunsicker LG, Clarke WR, et al: Renoprotective effecttion observed in CsA-treated animals, and that this effect
of the angiotensin-receptor antagonist irbesartan in patients withwas associated with a significant reduction of tubulointer-
nephropathy due to type 2 diabetes. N Engl J Med 345:851–860, 2001
stitial damage. 17. Brenner BM, Cooper ME, de Zeeuw D, et al: Effects of losartan
In conclusion, our findings show that aldosterone plays on renal and cardiovascular outcomes in patients with type 2 diabe-
tes and nephropathy. N Engl J Med 345:861–869, 2001a key role in producing functional and structural changes
18. Greene EL, Kren S, Hostetter TH: Role of aldosterone in theassociated with CsA nephrotoxicity, and points to miner- remnant kidney model in the rat. J Clin Invest 98:1063–1068, 1996
alocorticoid blockade as a potential treatment for reduc- 19. Rocha R, Chander PN, Khanna K, et al: Mineralocorticoid block-
ade reduces vascular injury in stroke-prone hypertensive rats. Hy-ing renal toxicity induced by CsA.
pertension 31:451–458, 1998
20. Rocha R, Chander PN, Zuckerman A, Stier CT Jr: Role of
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